TNFSF13B and autoimmune disease: Telitacicept is a novel fusion protein developed by Rongchang Pharmaceuticals, composed of the extracellular soluble domain of the TACI and the crystallizable fragment (Fc) of human immunoglobulin G [83].The TACI domain in the telitacicept molecule binds to and neutralizes two B cell activation molecules, BlyS and APRIL, effectively inhibiting overactive B cells and plasma cells in autoimmune diseases, thus limiting their production of autoantibodies [83].